Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00449306|
Recruitment Status : Active, not recruiting
First Posted : March 20, 2007
Last Update Posted : October 25, 2016
Lipid-rich atherosclerotic plaques, or "vulnerable plaques" are prone to rupture, causing local intravascular thrombosis, with subsequent grave clinical consequences. Atherosclerotic plaques normally removed during surgery, and peripheral blood samples will be studied to achieve the following objectives:
"1" Define histological features of the vulnerable plaque, analyze its physical characteristics, and investigate selected gene expression.
"2" Study biomarkers of inflammation in conjunction with the presence of vulnerable plaques.
"3" Explore the potential role of infection in atherogenesis.
|Condition or disease|
|Atherosclerosis Aortic Aneurysm Peripheral Vascular Diseases|
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Observational Model:||Case Control|
|Official Title:||Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques|
|Study Start Date :||March 2001|
|Estimated Primary Completion Date :||July 2017|
|Estimated Study Completion Date :||July 2018|
- To uncover mechanisms of cardiovascular diseases [ Time Frame: 3 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00449306
|Sheba Medical Center, Tel Hashomer|
|Ramat Gan, Israel, 52621|
|Principal Investigator:||Jacob Schneiderman, MD||Department of Vascular Surgery, Sheba Medical Center, Tel Hashomer|